Here are seven insights:
1. Integra LifeSciences’ offered a price of $1.05 billion in cash.
2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.
3. Integra hopes to combine Codman’s neurosurgery portfolio with its tissue ablation, dural repair and cranial stabilization products to offer a comprehensive neurosurgery portfolio.
4. In 2016, the Codman neurosurgery products generated about $370 million in revenue.
5. Integra anticipates the transaction to be accretive to adjusted earnings-per-share by $0.22 at least in the first full year post-closing.
6. While Integra expects the Codman Neurosurgery revenue to see some disruption in the first year after acquisition, the company believes it will increase 3 percent to 6 percent in the longer term.
7. After the information and consultation process with the employees’ representatives in other countries concludes, Integra plans to enter into a definitive purchase and sale agreement.
More articles on devices:
FDA grants Medtronic expanded indication for cancer-fighting OsteoCool Ablation System — 7 takeaways
FDA clears Centric Medical’s Metatarsal Hemi Implant System — 5 details
3-D printing for medical sector to grow at 11.7% CAGR through 2024: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
